Zamzam Al-Hashami Selected Research

Therapeutics

4/2023	Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults.
1/2023	Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
12/2022	Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
10/2022	Lung cancer screening in the gulf: Rationale and recommendations.
1/2022	Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.
1/2022	Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zamzam Al-Hashami Research Topics

Disease

5	Neoplasms (Cancer) 10/2023 - 01/2022
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2023 - 01/2021
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2022 - 01/2022
1	Disease Progression 01/2023
1	Lung Neoplasms (Lung Cancer) 10/2022
1	Tuberculosis (Tuberculoses) 01/2022
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Idiopathic Pulmonary Fibrosis 01/2022
1	Rheumatoid Arthritis 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Takayasu Arteritis (Arteritis, Takayasu's) 01/2022

Drug/Important Bio-Agent (IBA)

5	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2021
2	PlatinumIBA 01/2023 - 01/2022
2	pembrolizumabIBA 01/2023 - 11/2022
1	PM 01183IBA 12/2022
1	Biomarkers (Surrogate Marker)IBA 01/2021

Therapy/Procedure

6	Therapeutics 04/2023 - 01/2022
2	Drug Therapy (Chemotherapy) 01/2023 - 01/2022
1	Duration of Therapy 01/2023
1	Immunotherapy 01/2022
1	Contraindications 01/2022